The £4.22 billion bottleneck: why good data isn't enough to fix the OSA crisis.
The economic case for treating obstructive sleep apnoea is now irrefutable. The problem is no longer evidence. The problem is system design.
The analysis by Rehman and colleagues, quantifying the productivity loss from untreated obstructive sleep apnoea at £4.22 billion annually in the UK, is exactly the kind of data the NHS has been missing. Not because we lacked clinical evidence as OSA's relationship to cardiovascular disease, metabolic illness, and mental health has been documented for decades. What was missing was the economic argument in a language that NHS leadership could not ignore.
That argument is now available and it changes nothing by itself.
Identifying the constraint
The theory of constraints tells us that a system performs at the speed of its slowest point. Adding capacity anywhere else is waste until you address the bottleneck. In OSA care, the bottleneck is identification. Approximately 80% of cases remain undiagnosed. The referral pathway, the sleep study, the CPAP titration: none of these can function at scale if cases are not being recognised and sent through in the first place.
Primary care is the front door through which almost every undiagnosed OSA case must pass. And primary care, at present, is not structured to catch them. The average GP consultation offers limited time and competing priorities. OSA presents diffusely, for example with fatigue, low mood, hypertension, poor glycaemic control, and its cardinal symptom, snoring, is often normalised or embarrassing to report. Without active screening, most cases don't surface.
The siloed system problem
Rehman et al. correctly identify obesity as the primary modifiable driver of OSA. This is where the structural problem becomes acute. In the current NHS model, weight management services and sleep services are almost entirely separate: different referral pathways, different teams, different budgets, different waiting lists.
This is not a clinical failure. It is a design failure. Systems produce the outcomes their structure makes inevitable. Obesity and OSA interact profoundly and bidirectionally: sleep deprivation worsens metabolic function and appetite regulation, making obesity harder to treat; obesity worsens OSA severity. Treating these conditions in separate silos means treating each less effectively.
What a primary-care-led solution looks like
Primary care is uniquely positioned to address both prevention and early diagnosis, not because GPs have spare capacity (they do not), but because primary care is where the longitudinal relationship lives. The GP who has known a patient for years is the clinician most likely to notice the gradual accumulation of symptoms that individually seem unremarkable but together constitute a diagnosable sleep disorder.
Community-based oximetry, simple overnight home testing arrangeable without specialist referral, can dramatically reduce diagnostic delay. Combined with aggressive early access to weight management, this approach could reduce the burden on tertiary sleep centres and allow them to focus on the complex phenotypes that genuinely require specialist input.
The economic case is already made. Treating OSA costs £1,363 per affected worker per year. Ignoring it costs £1,840. The data from Rehman et al. has given us the argument we needed. The next question, are we willing to redesign the system to use it, is harder, and it is the one we now need to answer.
Developed from a rapid response published in Thorax, 16 April 2026, in response to: Rehman U, et al. Neglected burden of obstructive sleep apnoea: workplace productivity loss in the USA and UK. Thorax. 2026;81(5):492.View original rapid response →
